The US Food and Drug Administration (FDA) has granted priority review for the full approval of the antibody drug conjugate, Elahere (mirvetuximab soravtansine-gynx) and has set a Prescription Drug User Fee Act (PDUFA) action date of 5 April 2024.
Elahere was a central element in the $10.1bn ImmunoGen acquisition deal announced by last week (30 November). AbbVie expects the acquisition to complete in mid-2024.
Elahere is an antibody drug conjugate (ADC) that targets folate receptor alpha (FR伪). In November 2022, it was granted accelerated approval as the treatment of FR伪-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer for patients who have received one to three prior systemic treatment regimens.
The latest supplemental Biologics License Application (sBLA) for Elahere is supported by the , which will allow for the accelerated approval to be converted to a full approval.
reported $105.2m in net sales for Elahere in Q3 2023, and the therapy is forecasted to generate $1.43bn in global sales in 2029, as per GlobalData analysis.
GlobalData is the parent company of Pharmaceutical Technology.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe MIRASOL trial met its primary endpoint demonstrating a 35% reduction in the risk of tumour progression or death in the Elahere treatment group compared to the chemotherapy arm, as per a 4 June press release. The median overall survival was 16.46 months and 12.76 months for the Elahere and chemotherapy groups, respectively, as of 6 March.
The objective response rate by investigator assessment was 42.3% in Elahere arm, with 12 complete responses, compared to 15.9% and no complete responses in the chemotherapy arm. During the trial, 9% and 16% of the participants on the Elahere and chemotherapy arms discontinued the study due to treatment-emergent adverse events.
ADCs have been a growing area of interest in recent years, with multiple companies out-licencing and partnering to develop these therapies. In October, Eli Lilly agreed to acquire French biotech Mablink, which had a proprietary ADC development technology.
